PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28092916-9 2017 However, the levels of CD4+Foxp3+ and CD3-CD56+ T cells were higher in the brand-name tacrolimus group than in the generic tacrolimus group 8 weeks after transplantation (p < 0.05). Tacrolimus 86-96 CD4 molecule Homo sapiens 23-26 28257599-7 2017 Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control. Tacrolimus 15-25 CD4 molecule Homo sapiens 49-52 28092916-10 2017 CONCLUSIONS: The level of CD4+Foxp3+ T cells was higher in the brand-name tacrolimus group than in the generic tacrolimus group after transplantation. Tacrolimus 74-84 CD4 molecule Homo sapiens 26-29 28092916-10 2017 CONCLUSIONS: The level of CD4+Foxp3+ T cells was higher in the brand-name tacrolimus group than in the generic tacrolimus group after transplantation. Tacrolimus 111-121 CD4 molecule Homo sapiens 26-29 28092916-11 2017 This finding showed that brand-name tacrolimus could have more potential immunosuppressive activity than generic tacrolimus regarding the contribution of CD4+Foxp3+ T cells to graft tolerance in liver transplant recipients. Tacrolimus 36-46 CD4 molecule Homo sapiens 154-157 24279588-8 2014 On multivariate analyses, significant independent predictors for long-term impaired CD4 T-cell reconstitution were recipient age, pretransplant CD4+ T-cell count, 12-month CD4+ T-cell count, and tacrolimus or MMF therapy. Tacrolimus 195-205 CD4 molecule Homo sapiens 84-87 27569951-5 2016 CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups. Tacrolimus 32-37 CD4 molecule Homo sapiens 0-3 22141281-5 2011 TREC contents within double-positive cells and CD4+ single-positive cells were significantly decreased 4 M after tacrolimus therapy (p < 0.05) in PM/DM patients. Tacrolimus 113-123 CD4 molecule Homo sapiens 47-50 23743668-10 2013 Tacrolimus 10 ng/mL reduced the production of IL-2 in CD4 and CD8 T cells by 28.9% and 45.4% (P < 0.05). Tacrolimus 0-10 CD4 molecule Homo sapiens 54-57 23743668-12 2013 This effect on tacrolimus pharmacodynamics was associated with ABCB1 3435C>T SNP in renal transplant patients: verapamil reduced the percentage of IL-2-producing CD4 and CD8 T cells by 14% and 22% in patients with the CC genotype (P < 0.05) but not in patients with the TT genotype. Tacrolimus 15-25 CD4 molecule Homo sapiens 165-168 24157471-0 2014 Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. Tacrolimus 125-135 CD4 molecule Homo sapiens 74-77 24157471-9 2014 TEC-reactive CD4 T-cell proliferation was significantly suppressed by tacrolimus, everolimus, prednisolone, and MPA (P<0.05). Tacrolimus 70-80 CD4 molecule Homo sapiens 13-16 22141281-6 2011 Tacrolimus treatment significantly attenuated TREC content within cultured CD4+CD8- cells from PM/DMpatients (p < 0.05), but total cell counts were not significantly changed. Tacrolimus 0-10 CD4 molecule Homo sapiens 75-78 20524872-12 2011 In tacrolimus-treated cases, there was a decrease in CD4 and MHC II, with no change in CD8 between the pre- and post-treated areas. Tacrolimus 3-13 CD4 molecule Homo sapiens 53-56 20528886-8 2010 The rATG tacrolimus-induced CD25(+) T cells inhibited proliferative responses of alloantigen-stimulated effector T cells as vigorously as rATG-induced and natural CD4(+)CD25(+)FoxP3(+)CD127(-/low) T cells (67% +/- 18% versus 69% +/- 16% versus 45% +/- 20%, mean +/- standard error of the mean, respectively). Tacrolimus 9-19 CD4 molecule Homo sapiens 163-166 19557878-0 2009 Low-dose of tacrolimus favors the induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation. Tacrolimus 12-22 CD4 molecule Homo sapiens 58-61 19398001-1 2009 We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation. Tacrolimus 99-109 CD4 molecule Homo sapiens 48-51 20484893-8 2010 Statistically significant correlations between CD4+CD25(high)Foxp3+ Tregs and tacrolimus levels and CD4+CD25(high)Foxp3- Tregs and HLA-DR mismatching were detected. Tacrolimus 78-88 CD4 molecule Homo sapiens 47-50 19714314-0 2009 Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4(+) T cells. Tacrolimus 0-10 CD4 molecule Homo sapiens 85-88 19714314-2 2009 However, the exact pharmacological effects of tacrolimus on CD4(+) T cells have yet to be elucidated. Tacrolimus 46-56 CD4 molecule Homo sapiens 60-63 19714314-3 2009 This study investigated the effects of tacrolimus on CD4(+) T cell subsets. Tacrolimus 39-49 CD4 molecule Homo sapiens 53-56 19714314-7 2009 In the case of conventional CD4(+) T cells (Tconv cells), tacrolimus inhibited T cell receptor stimulation-induced cell division. Tacrolimus 58-68 CD4 molecule Homo sapiens 28-31 19714314-8 2009 In contrast, the cell division of regulatory CD4(+) T cells (Treg cells) was even promoted in the presence of tacrolimus, especially in humans. Tacrolimus 110-120 CD4 molecule Homo sapiens 45-48 17223872-6 2007 RESULTS: CD3+, CD4+ and CD8+ lymphocytes, and eosinophil and neutrophil granulocytes were significantly reduced in post-treatment tacrolimus specimens, while CD1a+ cells and mast cells were not. Tacrolimus 130-140 CD4 molecule Homo sapiens 15-18 19162189-10 2009 Immunohistochemistry revealed a high number of CD4+ cells and high CD4/CD8 ratio in grafts pre-treated with tacrolimus. Tacrolimus 108-118 CD4 molecule Homo sapiens 47-50 19162189-10 2009 Immunohistochemistry revealed a high number of CD4+ cells and high CD4/CD8 ratio in grafts pre-treated with tacrolimus. Tacrolimus 108-118 CD4 molecule Homo sapiens 67-70 19162189-11 2009 Donor pre-treatment with tacrolimus significantly reduces transplant arteriosclerosis and is associated with reduced in situ MMP-2/MMP-9 activity and increased number of CD4+ cells. Tacrolimus 25-35 CD4 molecule Homo sapiens 170-173 18845086-0 2008 [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. Tacrolimus 24-34 CD4 molecule Homo sapiens 46-49 18845086-1 2008 AIM: To explore the regulatory function of FK506 and CsA on CD4/CD8 T lymphocyte subgroups and co-stimulators on them. Tacrolimus 43-48 CD4 molecule Homo sapiens 60-63 12142035-3 2002 The calcineurin inhibitor FK506 at 1nM inhibited the development of thymocytes to either lineage, but 0.3nM FK506 significantly switched the development from the CD4 cell fate to the CD8 cell fate. Tacrolimus 108-113 CD4 molecule Homo sapiens 162-165 16054825-12 2005 The degree of donor leukocyte chimerism and the frequency of CD4+CD25+ T-cells were higher in the tacrolimus group, however, these differences were not statistically significant. Tacrolimus 98-108 CD4 molecule Homo sapiens 61-64 15899924-2 2005 Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection. Tacrolimus 33-38 CD4 molecule Homo sapiens 92-95 14966413-8 2004 FK506 reduced the expansion of donor CD8+ and, to a lesser extent, CD4+ T cells in the spleen and inhibited donor anti-host T-cell proliferative and cytotoxic responses. Tacrolimus 0-5 CD4 molecule Homo sapiens 67-70 11865967-6 2002 However, patients who were started on tacrolimus or cyclosporine had an initial decline in expression of P-gp on CD4 T cells. Tacrolimus 38-48 CD4 molecule Homo sapiens 113-116 10589954-3 1999 We have investigated the inhibitory effects of CsA and FK506 on the direct response of human CD4+ T cells to HUVEC and PAEC and the effect of adding B7-1 transfectants. Tacrolimus 55-60 CD4 molecule Homo sapiens 93-96 11053632-6 2000 Treatment with Tacr resulted in a decreased expression of costimulatory ligands and adhesion molecules (T cells: CD40L, p < 0.05; CD28 and CD54, p < or = 0.01; B cells: CD25, p = 0.05; CD40, p < 0.001; monocytes: CD40, p < 0.05), which coincided with decreased PHA-stimulated T cell IL-2 responses (398 +/- 153 versus 43 +/- 15 pg/ml, p < 0.05), impaired CD4 helper activity (117% +/- 22% versus 73% +/- 19%, p < 0.05) and increased CD4 suppressor activity (-120% +/- 28% versus -18% +/- 27%, p = 0.02). Tacrolimus 15-19 CD4 molecule Homo sapiens 113-116 11053632-6 2000 Treatment with Tacr resulted in a decreased expression of costimulatory ligands and adhesion molecules (T cells: CD40L, p < 0.05; CD28 and CD54, p < or = 0.01; B cells: CD25, p = 0.05; CD40, p < 0.001; monocytes: CD40, p < 0.05), which coincided with decreased PHA-stimulated T cell IL-2 responses (398 +/- 153 versus 43 +/- 15 pg/ml, p < 0.05), impaired CD4 helper activity (117% +/- 22% versus 73% +/- 19%, p < 0.05) and increased CD4 suppressor activity (-120% +/- 28% versus -18% +/- 27%, p = 0.02). Tacrolimus 15-19 CD4 molecule Homo sapiens 191-194 11053632-8 2000 Our data show that switching of immunosuppressive therapy from CsA to tacrolimus results in suppression of costimulatory ligands, adhesion molecules, Th1 responses and CD4 helper activity. Tacrolimus 70-80 CD4 molecule Homo sapiens 168-171 1721455-0 1991 FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. Tacrolimus 0-6 CD4 molecule Homo sapiens 74-77 9371682-5 1997 Increased thymic apoptosis resulted in the disappearance of CD4+CD8+ thymocytes after FK506/dexamethasone injection. Tacrolimus 86-91 CD4 molecule Homo sapiens 60-63 9123208-0 1997 Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. Tacrolimus 98-108 CD4 molecule Homo sapiens 36-39 7495746-0 1995 Cross-linking of the TCR-CD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506. Tacrolimus 134-139 CD4 molecule Homo sapiens 42-45 7495746-3 1995 As positive selection depends on the inhibition of thymocyte apoptosis at its DP stage by signaling through the TCR-CD3 complex and some of the accessory molecules, including CD4, CD8 and LFA-1, we studied the possibility that FK506 enhanced apoptosis by itself or canceled the inhibition of apoptosis. Tacrolimus 227-232 CD4 molecule Homo sapiens 175-178 7495746-5 1995 On the other hand, upon cross-linking TCR-CD3 together with CD4, CD8 or LFA-1, FK506 markedly enhanced DNA fragmentation and cytolysis. Tacrolimus 79-84 CD4 molecule Homo sapiens 60-63 7540862-0 1995 IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Tacrolimus 114-119 CD4 molecule Homo sapiens 19-22 7522130-5 1994 We suggest that IL2 secretion induced by antigen presentation to TCR/CD4/p56lck requires an FK506 and cyclosporin A-sensitive step which may be independent of calcium signaling. Tacrolimus 92-97 CD4 molecule Homo sapiens 69-72 11271304-0 1994 FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. Tacrolimus 0-6 CD4 molecule Homo sapiens 98-101 11271304-3 1994 Using 171, 171-CD4 (wild-type) and 171-CD4 (mutant), we found that IL-2 secretion was inhibited by FK 506 and cyclosporin but not by rapamycin. Tacrolimus 99-105 CD4 molecule Homo sapiens 15-18 11271304-3 1994 Using 171, 171-CD4 (wild-type) and 171-CD4 (mutant), we found that IL-2 secretion was inhibited by FK 506 and cyclosporin but not by rapamycin. Tacrolimus 99-105 CD4 molecule Homo sapiens 39-42 9103428-0 1997 IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. Tacrolimus 91-96 CD4 molecule Homo sapiens 61-64 7495746-7 1995 Cross-linking of TCR-CD3 together with CD4, CD8 or LFA-1 markedly inhibited glucocorticoid-induced death and the inhibition was canceled by FK506. Tacrolimus 140-145 CD4 molecule Homo sapiens 39-42 1911152-9 1991 Unfortunately, one of the most effective ingredients of such combination therapies in animal models (anti-CD4) appears to have its tolerogenic potential abrogated by cyclosporin A and FK-506. Tacrolimus 184-190 CD4 molecule Homo sapiens 106-109 34607938-9 2021 In vitro treatment of healthy CD4+ and CD8+ T cells with tacrolimus abrogated the proliferation and cytokine (INF-gamma, IL-2, and TNF-alpha) secretion associated with the type 1 inflammatory phenotype observed in pre- and post-PTx rejectors. Tacrolimus 57-67 CD4 molecule Homo sapiens 30-33 33638630-0 2021 CD28 confers CD4+ T cells with resistance to cyclosporin A and tacrolimus but to different degrees. Tacrolimus 63-73 CD4 molecule Homo sapiens 13-16 33638630-9 2021 RESULTS: Anti-CD28 mAb conferred CD4+ T cells with resistance to both CSA and TAC, and CD28"s effect on the latter was approximately twice that on the former. Tacrolimus 78-81 CD4 molecule Homo sapiens 33-36 33638630-11 2021 The addition of LPS to culture containing DCs seemed to make CD4+ T cells slightly resistant to TAC but not to CSA. Tacrolimus 96-99 CD4 molecule Homo sapiens 61-64 30597187-8 2019 Patients who received Tac/MMF had significantly higher CD4+ CD25+ FOXP3+ Treg cells compared to patients who received Tac/SRL. Tacrolimus 22-25 CD4 molecule Homo sapiens 55-58 30633591-5 2019 Results: It is found that percentages of CD3+, CD3+CD4+ and CD3+CD8+ T cells in FK506 group are lowered compared to the control group but they are elevated in FK506 + MMF group. Tacrolimus 80-85 CD4 molecule Homo sapiens 51-54 30633591-6 2019 Amount of CD4+CD25+CD127low/-Treg cells in CD3+ CD4+T cells in FK506 + MMF group was higher than that in FK506 group and control group. Tacrolimus 63-68 CD4 molecule Homo sapiens 10-13 30633591-6 2019 Amount of CD4+CD25+CD127low/-Treg cells in CD3+ CD4+T cells in FK506 + MMF group was higher than that in FK506 group and control group. Tacrolimus 63-68 CD4 molecule Homo sapiens 48-51 30633591-6 2019 Amount of CD4+CD25+CD127low/-Treg cells in CD3+ CD4+T cells in FK506 + MMF group was higher than that in FK506 group and control group. Tacrolimus 105-110 CD4 molecule Homo sapiens 10-13 30633591-6 2019 Amount of CD4+CD25+CD127low/-Treg cells in CD3+ CD4+T cells in FK506 + MMF group was higher than that in FK506 group and control group. Tacrolimus 105-110 CD4 molecule Homo sapiens 48-51 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 CD4 molecule Homo sapiens 52-55 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 CD4 molecule Homo sapiens 217-220 34335631-7 2021 In that group, absolute CD4+CD25+CD127-Foxp3+ Tregs were negatively associated with steroid dose and tacrolimus trough levels (r=-0.377, p = 0.021, n=37; r=-0.43, p=0.033, n=25, respectively), opposite to IL-10+ Bregs, whose frequency apparently was not negatively affected by potent immunosuppression early posttransplant. Tacrolimus 101-111 CD4 molecule Homo sapiens 24-27 33729741-10 2021 Patients lacking detectable SARS-CoV-2-specific CD4 response by month 6 were more likely to be under tacrolimus (100.0% versus 66.7%; P-value = 0.087) and to have received tocilizumab for the previous COVID-19 episode (40.0% versus 0.0%; P-value = 0.087). Tacrolimus 101-111 CD4 molecule Homo sapiens 48-51 32425928-8 2020 Interestingly, when we compared the ability of Mo-MDSC to suppress T cell proliferation, we observed that tacrolimus, but not rapamycin-treated KTR, was able to inhibit CD4+ T cell proliferation in vitro. Tacrolimus 106-116 CD4 molecule Homo sapiens 169-172 30293884-7 2019 At week 24, peripheral blood CD4+CD25+high T cells with tacrolimus decreased significantly (P<0.01), but increased significantly without tacrolimus (P<0.01). Tacrolimus 56-66 CD4 molecule Homo sapiens 29-32